Holen Sie sich die Stockscreener-App
95.88
0.23%
-0.22
Handel nachbörslich:
95.97
0.09
+0.09%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$96.10
Offen:
$95.99
24-Stunden-Volumen:
1.21M
Relative Volume:
0.75
Marktkapitalisierung:
$47.57B
Einnahmen:
$9.91B
Nettoeinkommen (Verlust:
$1.02B
KGV:
46.77
EPS:
2.05
Netto-Cashflow:
$665.00M
1W Leistung:
-0.30%
1M Leistung:
+15.69%
6M Leistung:
+3.53%
1J Leistung:
+19.33%
1-Tages-Spanne:
$95.38
$97.14
1-Wochen-Bereich:
$95.12
$99.20
52-Wochen-Spanne:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
95.88 | 47.57B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
538.16 | 185.37B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
167.95 | 48.59B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
243.09 | 35.70B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.92 | 16.51B | 3.90B | 392.30M | 288.10M | 1.95 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Nasdaq
Fund Update: THORNBURG INVESTMENT MANAGEMENT INC added 249,767 shares of ALCON ($ALC) to their portfolio - Nasdaq
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance - Stock Titan
Alcon Announces Results of 2025 Annual General Meeting | ALC Stock News - GuruFocus
Alcon Announces Results of 2025 Annual General Meeting - Business Wire
Institutional investors are Alcon Inc.'s (VTX:ALC) biggest bettors and were rewarded after last week's CHF1.2b market cap gain - simplywall.st
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL.com
Do Options Traders Know Something About Alcon Stock We Don't? - Yahoo Finance
RBC Bets On Alcon's Growth With Continued Outperform Rating - Finimize
RBC Keeps Alcon at Outperform Ahead of Q1 Results - marketscreener.com
Alcon (ALC) Gets a Buy from RBC Capital - The Globe and Mail
Alcon Rolls Out Unity Vitreoretinal and Cataract Surgery Systems - Medical Product Outsourcing
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior E - GuruFocus
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS - marketscreener.com
Corneal Topographers Market Deep Research 2025-2032 | Alcon plc., Abbott Laboratories, Topcon Corporation - openPR.com
WCO & Alcon Dry Eye Wheel launches in French - childrennow.co.uk
Village Roadshow’s $417.5 Million Stalking Horse Deal Approved - Bloomberg.com
Alcon Entertainment Appoints Former MGM Exec Steven Johnson As EVP, Head Of Physical Production - IMDb
Alcon lines up product launches in India, bets on rising demand for advanced eye care - MSN
Lobbying Update: $150,000 of ALCON VISION LLC lobbying was just disclosed - Nasdaq
Aniridia Treatment Market Is Going to Boom | Major Giants Alcon, Santen Pharmaceutical, Johnson & Johnson Vision - openPR.com
There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital - Yahoo Finance
Alcon: A Clear Vision, But Fully Valued (NYSE:ALC) - Seeking Alpha
GE HealthCare Hires Alcon Exec Jeannette Bankes as Patient Care Solutions CEO - Medical Product Outsourcing
High-level Milwaukee-area GE HealthCare exec to retire - The Business Journals
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC) - Insider Monkey
Tesla, Warner Bros fend off some claims in 'Blade Runner 2049' ad dispute - Reuters
Alcon (VTX:ALC) Seems To Use Debt Quite Sensibly - simplywall.st
Alcon Scoops Up Aurion Biotech With Intent of Advancing Ophthalmology Cell Therapy AURN001 - CGTLive®
US Tariffs Challenge Carl Zeiss Meditec And Smith & Nephew - Finimize
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 - Investing.com Canada
Alcon, Aurion Reach Accord in Dispute Over Public Offering - Bloomberg Law News
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 By Investing.com - Investing.com South Africa
Dr. Jeffrey Martin of SightMD Becomes One of the First on Long Island to Implant the new Clareon® PanOptix® Pro Lens by Alcon - PRWeb
Alcon Publishes Agenda for 2025 Annual General Meeting - Business Wire
ALC Stock May Rise With the Introduction of PanOptix Pro in US - MSN
Alcon Introduces Clareon PanOptix Pro Intraocular Lens - Medical Product Outsourcing
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix - GuruFocus
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter – Company AnnouncementFT.com - Financial Times
Game-Changing Cataract Lens: Alcon's New PanOptix Pro Achieves Record 94% Light Efficiency - Stock Titan
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Dry Eye Disease Market Growth in Future Scope 2025-2032 | - openPR.com
KeyBanc raises Alcon stock price target to $112 on growth outlook - Investing.com Canada
KeyBanc raises Alcon stock price target to $112 on growth outlook By Investing.com - Investing.com South Africa
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):